{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:46:39Z","timestamp":1793969199021,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1U24AG057437"],"award-info":[{"award-number":["1U24AG057437"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40263-023-01021-8","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T05:01:36Z","timestamp":1689829296000},"page":"671-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer\u2019s Disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Solana","family":"Leisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Bohorquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renarda","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobri","family":"Baldaranov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2094","authenticated-orcid":false,"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"1021_CR1","unstructured":"World Health Organization. Dementia. Published September 21, 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia. Accessed 23 Apr 2023."},{"key":"1021_CR2","doi-asserted-by":"publisher","unstructured":"2021 Alzheimer's Disease Facts and Figures\u2014Wiley Online Library. https:\/\/doi.org\/10.1002\/alz.12328. Published March 23, 2021.","DOI":"10.1002\/alz.12328"},{"issue":"4","key":"1021_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","volume":"19","author":"Alzheimer's disease facts and figures","year":"2023","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2023;19(4):1598\u2013695.","journal-title":"Alzheimers Dement"},{"key":"1021_CR4","unstructured":"FDA grants accelerated approval for Alzheimer's drug. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug. Published June 7, 2021. Accessed 18 Aug 2022."},{"issue":"1","key":"1021_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2017;9(1):60. https:\/\/doi.org\/10.1186\/s13195-017-0283-5.","journal-title":"Alzheimers Res Ther."},{"issue":"2","key":"1021_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1021_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"23","key":"1021_CR8","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack Jr","year":"2019","unstructured":"Jack CR Jr, Wiste HJ, Therneau TM, et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA. 2019;321(23):2316\u201325. https:\/\/doi.org\/10.1001\/jama.2019.7437.","journal-title":"JAMA"},{"key":"1021_CR9","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation Early Alzheimer\u2019s Disease: developing drugs for treatment, guidelines for industry. 2018. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM596728.pdf. Accessed 23 Apr 2023."},{"issue":"9","key":"1021_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205\u201335. https:\/\/doi.org\/10.1038\/aps.2017.28.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"1021_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/pin.12520","volume":"67","author":"RH Takahashi","year":"2017","unstructured":"Takahashi RH, Nagao T, Gouras GK. Plaque formation and the intraneuronal accumulation of \u03b2-amyloid in Alzheimer\u2019s disease. Pathol Int. 2017;67(4):185\u201393. https:\/\/doi.org\/10.1111\/pin.12520.","journal-title":"Pathol Int"},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fncel.2015.00191","volume":"9","author":"ST Ferreira","year":"2015","unstructured":"Ferreira ST, Lourenco MV, Oliveira MM, et al. Soluble amyloid-\u03b2 oligomers as synaptotoxins leading to cognitive impairment in Alzheimer\u2019s disease. Front Cell Neurosci. 2015;9:191. https:\/\/doi.org\/10.3389\/fncel.2015.00191.","journal-title":"Front Cell Neurosci"},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"U Sengupta","year":"2016","unstructured":"Sengupta U, Nilson AN, Kayed R. The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy. EBioMedicine. 2016;6:42\u20139. https:\/\/doi.org\/10.1016\/j.ebiom.2016.03.035.","journal-title":"EBioMedicine"},{"issue":"3","key":"1021_CR14","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/archneur.55.3.294","volume":"55","author":"D Blacker","year":"1998","unstructured":"Blacker D, Tanzi RE. The genetics of Alzheimer disease: current status and future prospects. Arch Neurol. 1998;55(3):294\u20136.","journal-title":"Arch Neurol"},{"issue":"11","key":"1021_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea J, Zaman SH, Hartley S, et al. Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021;20(11):930\u201342.","journal-title":"Lancet Neurol"},{"issue":"5","key":"1021_CR16","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1073\/pnas.0904532106","volume":"107","author":"RP Friedrich","year":"2010","unstructured":"Friedrich RP, Tepper K, R\u00f6nicke R, et al. Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci U S A. 2010;107(5):1942\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1021_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40336-018-0290-y","volume":"6","author":"N Okamura","year":"2018","unstructured":"Okamura N, Harada R, Ishiki A, et al. The development and validation of tau PET tracers: current status and future directions. Clin Transl Imaging. 2018;6(4):305\u201316.","journal-title":"Clin Transl Imaging."},{"issue":"7","key":"1021_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14(7):399\u2013415.","journal-title":"Nat Rev Neurol"},{"key":"1021_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","volume":"52","author":"SH Barage","year":"2015","unstructured":"Barage SH, Sonawane KD. Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer\u2019s disease. Neuropeptides. 2015;52:1\u201318.","journal-title":"Neuropeptides"},{"issue":"2","key":"1021_CR20","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2022;9(2):197\u2013210.","journal-title":"J Prev Alzheimers Dis."},{"key":"1021_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alz Res Therapy. 2021;13:80.","journal-title":"Alz Res Therapy"},{"issue":"1","key":"1021_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"key":"1021_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12748","author":"MS Rafii","year":"2022","unstructured":"Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3\u201345 Study: Design of a prevention trial for Alzheimer\u2019s disease [published online ahead of print, 2022 Aug 15]. Alzheimers Dement. 2022. https:\/\/doi.org\/10.1002\/alz.12748.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"1021_CR24","first-page":"414","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) phase 1b study In Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8(4):414\u201324.","journal-title":"J Prev Alzheimers Dis."},{"issue":"18","key":"1021_CR25","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"2","key":"1021_CR26","first-page":"211","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J Prev Alzheimers Dis. 2022;9(2):211\u201320.","journal-title":"J Prev Alzheimers Dis."},{"issue":"4","key":"1021_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367\u201385.","journal-title":"Alzheimers Dement"},{"issue":"24","key":"1021_CR28","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1212\/WNL.0b013e3181e396ea","volume":"74","author":"JD Goos","year":"2010","unstructured":"Goos JD, Henneman WJ, Sluimer JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology. 2010;74(24):1954\u201360.","journal-title":"Neurology"},{"issue":"4","key":"1021_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000511506","volume":"49","author":"A Tian Hui Kwan","year":"2020","unstructured":"Tian Hui Kwan A, Arfaie S, Therriault J, et al. Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials. Dement Geriatr Cogn Disord. 2020;49(4):334\u201348.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"1021_CR30","first-page":"150","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici G, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(1):150\u201361.","journal-title":"J Prev Alzheimers Dis."},{"issue":"2","key":"1021_CR31","first-page":"221","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221\u201330.","journal-title":"J Prev Alzheimers Dis."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01021-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01021-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T12:28:51Z","timestamp":1692361731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01021-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01021-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"21 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by SCELC, Statewide California Electronic Library Consortium. This work was supported by Grant U24AG057437.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Solana Leisher, Adriana Bohorquez, Marcus Gay, Victoria Garcia, Renarda Jones, and Dobri Baldaranov have nothing to disclose. Michael S. Rafii reports consulting for AC Immune, Alzheon, Aptah Bio, Biohaven, Ionis, and Keystone Bio.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability Of Data And Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Solana Leisher, Adriana Bohorquez, Marcus Gay, Victoria Garcia, Renarda Jones, Dobri Baldaranov and Michael S. Rafii contributed to this manuscript. All contributed to literature search, drafting and revisions.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}